Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells
- PMID: 24325739
- DOI: 10.1111/jgh.12484
Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells
Abstract
Background and aim: Cancer stem cells (CSCs), a minority population with stem cell-like characteristics, play important roles in cancer development and progression. Putative CSC markers, such as CD13, CD90, CD133, and epithelial cell adhesion molecule (EpCAM), and side population (SP) technique are generally used in an attempt to isolate CSCs. We aimed to clarify the relationship between CSCs and clonal dedifferentiation in hepatocellular carcinoma (HCC).
Methods: We used a well-differentiated HCC cell line (HAK-1A) and a poorly differentiated HCC cell line (HAK-1B) established from a single nodule with histological heterogeneity. HAK-1B arose because of clonal dedifferentiation of HAK-1A. The SP cells and non-SP (NSP) cells were isolated from the two cell lines with a FACSAria II and used for the analyses.
Results: The SP cell fractions in HAK-1A and HAK-1B were 0.2% and 0.9%, respectively. CD90 or EpCAM was not expressed in either HAK-1A or HAK-1B, while CD13 and CD133 were expressed in HAK-1B alone. Although sphere forming ability, tumorigenicity, growth rate, and CD13 expression were higher in HAK-1B SP cells than HAK-1B NSP cells, there were no differences in drug resistance, colony forming ability, or cell cycle rates between HAK-1B SP and NSP cells, suggesting HAK-1B SP cells do not fulfill CSC criteria.
Conclusions: Our findings suggested a possible relationship between the expression of CSC markers and clonal dedifferentiation. However, the complete features of CSC could not be identified in SP cells, and the concept of SP cells as a universal marker for CSC may not apply to HAK-1A and HAK-1B.
Keywords: cancer stem cells; dedifferentiation; side population cells.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.
Similar articles
-
Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.BMC Cancer. 2015 Apr 11;15:260. doi: 10.1186/s12885-015-1297-7. BMC Cancer. 2015. PMID: 25885470 Free PMC article.
-
Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells.Hepatology. 1993 Aug;18(2):320-7. Hepatology. 1993. PMID: 8393423
-
Identification and characterization of tumorigenic liver cancer stem/progenitor cells.Gastroenterology. 2007 Jun;132(7):2542-56. doi: 10.1053/j.gastro.2007.04.025. Epub 2007 Apr 15. Gastroenterology. 2007. PMID: 17570225
-
[Progress and prospects in cancer stem cell research for hepatocellular carcinoma].Ai Zheng. 2009 Sep;28(9):1004-8. doi: 10.5732/cjc.008.10835. Ai Zheng. 2009. PMID: 19728923 Review. Chinese.
-
Biology and clinical implications of CD133(+) liver cancer stem cells.Exp Cell Res. 2013 Jan 15;319(2):126-32. doi: 10.1016/j.yexcr.2012.09.007. Epub 2012 Sep 19. Exp Cell Res. 2013. PMID: 22999864 Review.
Cited by
-
Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression.PLoS One. 2016 Mar 8;11(3):e0150336. doi: 10.1371/journal.pone.0150336. eCollection 2016. PLoS One. 2016. PMID: 26954680 Free PMC article.
-
Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2.Biosci Rep. 2018 Nov 9;38(6):BSR20180854. doi: 10.1042/BSR20180854. Print 2018 Dec 21. Biosci Rep. 2018. PMID: 30120100 Free PMC article.
-
Research progress and prospects of markers for liver cancer stem cells.World J Gastroenterol. 2015 Nov 14;21(42):12190-6. doi: 10.3748/wjg.v21.i42.12190. World J Gastroenterol. 2015. PMID: 26576103 Free PMC article. Review.
-
CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy.Oncol Res. 2020 Dec 10;28(5):533-540. doi: 10.3727/096504020X15919605976853. Epub 2020 Jun 12. Oncol Res. 2020. PMID: 32532363 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous